GSK to divest meningitis shots in exchange for EU clearance of Novartis deal

The European Commission has cleared GlaxoSmithKline's ($GSK) deal for most of Novartis' ($NVS) vaccines unit--on a couple of conditions. Glaxo has agreed to divest meningitis vaccines Nimenrix and Mencevax, marketed outside the U.S.; the duo generated £36 million ($54.7 million) in 2013. The British drugmaker will also part with two small bivalent vaccines sold in Italy and Germany that protect against diphtheria and tetanus, it said. Release

Suggested Articles

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.

Takeda has spent considerable resources on its phase 3 dengue vaccine, and now data show the shot was 80% effective in preventing dengue.